Clinton Musil joined Personalis in January 2019 as Chief Business Officer.  Mr. Musil previously worked at ARMO Biosciences, where he oversaw the Company’s $147 million initial public offering and $1.6 billion sale to Eli Lilly. Clinton has expertise in corporate finance and mergers and acquisitions (M&A) from the healthcare industry, including raising several billion dollars in equity and advising on more than $35 billion in M&A transactions.  Prior to joining ARMO, Mr. Musil was a Managing Director at Hercules Capital where he provided capital to life sciences companies at multiple stages of development. Clinton brings an extensive background in healthcare investment banking from several global, full service firms as well as experience as an investor at Essex Woodlands, a healthcare-dedicated fund.  Earlier in his career, Mr. Musil served in various positions at Gilead Sciences, Inc. and Sanofi S.A.  Mr. Musil received a B.S. in Molecular and Cellular Biology from the University of Arizona and an M.B.A. from Harvard Business School.